Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intensity Therapeutics Inc (INTS)

Intensity Therapeutics Inc (INTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,227
  • Shares Outstanding, K 2,540
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,610 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 3.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.50
  • Number of Estimates 1
  • High Estimate $-1.50
  • Low Estimate $-1.50
  • Prior Year $-5.50
  • Growth Rate Est. (year over year) +72.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.08 +10.24%
on 04/07/26
7.92 -29.29%
on 03/12/26
-2.17 (-27.93%)
since 03/09/26
3-Month
5.08 +10.24%
on 04/07/26
11.07 -49.42%
on 01/20/26
-4.79 (-46.09%)
since 01/09/26
52-Week
4.63 +20.89%
on 08/01/25
50.00 -88.80%
on 04/16/25
-42.90 (-88.45%)
since 04/09/25

Most Recent Stories

More News
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

SHELTON, Conn. , March 27, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

SHELTON, Conn. , March 24, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. , (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery...

INTS : 5.60 (+1.82%)
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

SHELTON, Conn. , March 12, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

SHELTON, Conn. , March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)
Intensity Therapeutics Announces Reverse Stock Split

Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026

INTS : 5.60 (+1.82%)
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026

INTS : 5.60 (+1.82%)
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn. , Dec. 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

SHELTON, Conn. , Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn. , Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SHELTON, Conn. , Nov. 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 5.60 (+1.82%)

Business Summary

Intensity Therapeutics Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx(SM) technology platform to create new, proprietary drug formulations, following direct injection, rapidly disperse throughout a tumor...

See More

Key Turning Points

3rd Resistance Point 5.97
2nd Resistance Point 5.86
1st Resistance Point 5.73
Last Price 5.60
1st Support Level 5.49
2nd Support Level 5.38
3rd Support Level 5.25

See More

52-Week High 50.00
Fibonacci 61.8% 32.67
Fibonacci 50% 27.32
Fibonacci 38.2% 21.96
Last Price 5.60
52-Week Low 4.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.